When is the Symbicort Patent Expected to Expire?
The primary patents for Symbicort, an inhaler used to treat asthma and chronic obstructive pulmonary disease (COPD), have largely expired or are nearing expiration in major markets. For instance, in the United States, many of the key patents have already expired, with the last of the original patents related to the active ingredients and formulation expiring around December 2023 [1].
What Does Patent Expiry Mean for Symbicort?
The expiration of Symbicort's patents opens the door for generic versions of the medication to enter the market. This typically leads to increased competition and potentially lower prices for consumers and healthcare systems [2].
Are There Other Exclusivity Protections for Symbicort?
Beyond the primary patents, other forms of market exclusivity can exist. For example, in the U.S., there is a 5-year Hatch-Waxman exclusivity for new uses, and a 7-year exclusivity for orphan drugs, neither of which appears to apply to the original Symbicort indication [3]. Information on specific patent landscapes and remaining exclusivities can be found on DrugPatentWatch.com [1].
What are the Implications for Generic Symbicort Development?
The expiration of patents allows pharmaceutical companies to develop and seek approval for generic equivalents of Symbicort. These generic versions must demonstrate bioequivalence to the branded drug to gain regulatory approval [2]. The availability of generic alternatives can significantly impact the market share and pricing of the originator product.
Who are the Competitors for Symbicort?
With patent expiry, competitors in the form of generic Symbicort inhalers are emerging. Additionally, Symbicort competes in the broader market of inhaled corticosteroids and long-acting beta-agonists with other branded and generic combination inhalers for asthma and COPD management [3].
What is the Active Ingredient in Symbicort?
Symbicort is a combination inhaler containing budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta-agonist [1].
---
Sources:
[1] DrugPatentWatch.com - https://drugpatentwatch.com/
[2] U.S. Food and Drug Administration - https://www.fda.gov/
[3] Astrazeneca - https://www.astrazeneca.com/